LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Начало・Списък с акции・MediciNova Inc

MediciNova Inc

Затворен

СекторЗдравеопазване

1.53 1.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.5

Максимум

1.54

Ключови измерители
By Trading Economics
Приходи	6.1B -3.1M
Продажби	-11K 123K
EPS	-0.06
Марж на печалбата	-2,473.563
Служители	13
EBITDA	599K -3M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	4.9M 74M
Предишно отваряне	0.21
Предишно затваряне	1.53

Настроения в новините

By Acuity

42%

58%

126 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

1.48 / 1.5599 Подкрепа & съпротива

MediciNova Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.12.2025 г., 00:04 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

12.12.2025 г., 16:42 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

13.12.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 08:00 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 07:00 ч. UTC

Придобивния, сливания и поглъщания

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13.12.2025 г., 00:24 ч. UTC

Придобивния, сливания и поглъщания

Want a Piece Of SpaceX? -- Barrons.com

12.12.2025 г., 23:49 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12.12.2025 г., 22:52 ч. UTC

Пазарно говорене

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12.12.2025 г., 22:32 ч. UTC

Печалби

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.12.2025 г., 20:45 ч. UTC

Печалби

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12.12.2025 г., 20:41 ч. UTC

Пазарно говорене

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12.12.2025 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12.12.2025 г., 19:23 ч. UTC

Печалби

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12.12.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12.12.2025 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12.12.2025 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12.12.2025 г., 17:49 ч. UTC

Печалби

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12.12.2025 г., 17:34 ч. UTC

Придобивния, сливания и поглъщания

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12.12.2025 г., 17:33 ч. UTC

Придобивния, сливания и поглъщания

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12.12.2025 г., 17:33 ч. UTC

Придобивния, сливания и поглъщания

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12.12.2025 г., 17:32 ч. UTC

Придобивния, сливания и поглъщания

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12.12.2025 г., 17:31 ч. UTC

Придобивния, сливания и поглъщания

Orange to Buy the Stake for EU4.25B in Cash

12.12.2025 г., 17:24 ч. UTC

Пазарно говорене

Argentina Predicts Record Wheat Crop -- Market Talk

12.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

12.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.12.2025 г., 17:18 ч. UTC

Пазарно говорене

Печалби

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12.12.2025 г., 17:09 ч. UTC

Пазарно говорене

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12.12.2025 г., 17:09 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

12.12.2025 г., 16:47 ч. UTC

Пазарно говорене

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MediciNova Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на MediciNova Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.48 / 1.5599Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

126 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.